EIGR Eiger Bio Pharmaceuticals, Inc. gains 21% Sep 5, 2018

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. It portfolio of products include Sarasar, an indication for the hepatitis delta virus infection; Exendin, which is used for the treatment of hypoglycemia associated with bariatric surgery; and Bestatin that is used for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.http://www.priceseries.com/trade/EIGR-Eiger-Bio-Pharmaceuticals-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2018081420180905.html